Single-Use Device Reprocessing & Remanufacturing: FDA & EU MDR Regulatory Guide (2026)

Overview: The Single-Use Device Reprocessing Landscape

Single-use device (SUD) reprocessing is one of the most consequential -- and sometimes misunderstood -- practices in the medical device industry. It sits at the intersection of regulatory science, healthcare economics, and environmental sustainability, and it has been the subject of intense debate among manufacturers, healthcare providers, regulators, and patient advocacy groups for decades.

The practice began in United States hospitals in the late 1970s, driven by a straightforward economic motivation: many devices labeled "single use" by their original manufacturers were being cleaned, sterilized, and reused by hospitals seeking to reduce costs. Over time, third-party reprocessors emerged as specialized companies that could perform this work with greater consistency and regulatory compliance than individual hospital sterile processing departments.

Today, SUD reprocessing is a regulated, legitimate industry. The FDA treats third-party reprocessors -- and hospitals that reprocess their own devices -- identically to original equipment manufacturers (OEMs) for regulatory purposes. In the European Union, reprocessing is governed by Article 17 of the Medical Device Regulation (EU) 2017/745, with significant changes proposed in 2025-2026 that could harmonize rules across all member states.

This guide provides a comprehensive examination of the regulatory frameworks governing SUD reprocessing in both the United States and the European Union, the economic and environmental case for reprocessing, the technical challenges involved, and the practical steps needed to bring a reprocessed device to market.

What Is Single-Use Device Reprocessing?

Definitions

A single-use device (SUD) is a medical device that the original manufacturer has labeled as intended for one use only, on a single patient, during a single procedure. The "single use" or "do not reuse" labeling is determined by the OEM based on their risk assessment, design validation, and intended use.

Reprocessing, in the context of SUDs, refers to the process of cleaning, repairing (if necessary), sterilizing or disinfecting, packaging, and labeling a previously used single-use device so that it can be used again. The term encompasses every step required to return the device to a condition suitable for clinical use.

Remanufacturing is a related but sometimes distinct concept. Under the EU MDR, the term "reprocessing" covers what the FDA framework describes, while "remanufacturing" is sometimes used to describe more extensive activities. The 2026 EU proposed amendment introduces the term "fully refurbished medical devices" to describe reprocessed SUDs, reflecting a terminological shift in the European framework.

The OEM Perspective vs. The Reprocessor Perspective

OEMs and reprocessors approach SUD reprocessing from fundamentally different positions:

• OEMs designate devices as single-use based on their design validation, materials testing, and risk analysis. They argue that reuse may compromise device performance, sterility, or biocompatibility in ways that cannot be fully controlled by reprocessing.
• Reprocessors argue that many SUDs are technically capable of withstanding multiple use cycles when subjected to rigorous cleaning, testing, and sterilization processes. They point to decades of clinical data and FDA oversight as evidence that properly reprocessed devices are as safe and effective as new ones.

The FDA has taken a clear position: "reprocessed SUDs that meet FDA's regulatory requirements are as safe and effective as a new device" (FDA, 2006). The U.S. Government Accountability Office (GAO) has similarly determined that available data do not indicate an elevated health risk to patients from the use of reprocessed SUDs.

Types of Reprocessors

There are two categories of reprocessors under FDA regulations:

Type	Description	Examples
Third-party reprocessors	Independent companies that collect, reprocess, and redistribute SUDs to healthcare facilities	Innovative Health, Cardinal Health Sustainable Technologies, Vanguard AG
Hospital reprocessors	Healthcare facilities that reprocess SUDs in-house for their own use	Hospital sterile processing departments that reprocess devices under their own establishment registration

Both are subject to the same regulatory requirements as OEMs. The Association of Medical Device Reprocessors (AMDR) serves as the industry trade association for third-party reprocessors.

The Business Case: Cost Savings and Sustainability

Cost Savings

The economic argument for SUD reprocessing is significant and well-documented:

• 30-50% savings on device acquisition costs. Healthcare facilities that use reprocessed SUDs can reduce their per-device spending by roughly one-third to one-half compared to purchasing new OEM devices. For high-volume surgical and diagnostic devices, these savings accumulate rapidly.
• Budget predictability. Reprocessing contracts often offer stable pricing that is less subject to the supply chain disruptions and price increases that affect new device markets.
• No compromise in clinical outcomes when properly regulated. FDA's regulatory framework requires reprocessors to demonstrate that reprocessed devices perform equivalently to new devices before they can be marketed.

For a mid-sized hospital performing thousands of procedures annually, reprocessing can translate into hundreds of thousands of dollars in savings each year. The savings are particularly meaningful for devices used in electrophysiology, cardiology, orthopedics, and general surgery.

Environmental Impact and Circular Economy

The environmental case is equally compelling. Medical waste is a growing concern worldwide, and single-use devices contribute substantially to the waste stream:

• Reduced medical waste. Each reprocessed device that is reused avoids the disposal of the original used device and the manufacturing of a replacement device. This reduces the volume of medical waste requiring treatment, incineration, or landfill.
• Conservation of non-renewable resources. Medical devices contain plastics, metals (including titanium and stainless steel), and other materials derived from non-renewable resources. Reprocessing extends the useful life of these materials.
• Lower carbon footprint. Manufacturing a new device requires raw material extraction, processing, manufacturing, packaging, sterilization, and transportation. Reprocessing avoids most of these steps, resulting in a lower overall carbon footprint per use.
• Circular economy alignment. SUD reprocessing is one of the most direct examples of circular economy principles applied in healthcare -- devices are recovered, restored, and returned to clinical use rather than discarded after a single use.

The environmental benefits are increasingly important as healthcare systems worldwide face pressure to reduce their environmental impact. Several major health systems now include reprocessing as part of their sustainability programs.

Recommended Reading

Missed the May 26, 2024 MDR Notified Body Deadline? Your Emergency Exit Options for Legacy MDD Devices

EU MDR / IVDR Notified Body2026-04-10 · 13 min read

FDA Regulatory Framework for SUD Reprocessing

Foundational Principle: Equal Regulatory Treatment

The foundational principle of FDA's approach to SUD reprocessing is that reprocessors are held to the same regulatory standards as original equipment manufacturers. This means that any entity -- whether a third-party company or a hospital -- that reprocesses a single-use device for reuse is considered a "manufacturer" under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and must comply with all applicable requirements.

This principle was not always enforced consistently. Prior to 2000, reprocessing existed in a regulatory gray area. In 2000, the FDA issued enforcement guidance establishing a phased approach to regulating reprocessors as manufacturers, with enforcement beginning in 2001. The Medical Device User Fee and Modernization Act (MDUFMA) of 2002 subsequently codified validation data requirements for reprocessed SUDs into law.

Historical Enforcement Timeline

FDA enforcement of SUD reprocessing requirements was phased in by device class:

Device Class	Enforcement Date	Premarket Requirement
Class III	February 2001	PMA or 510(k) required
Class II	August 2001	510(k) required
Class I	February 2002	510(k) required (even if OEM was exempt)

This phased approach, established by FDA guidance in 2000, gave reprocessors time to develop the technical data and submissions necessary for compliance. MDUFMA later codified these requirements into law. Importantly, even devices that are 510(k)-exempt when sold new by the OEM lose their exemption when reprocessed. A reprocessor must submit a 510(k) for a Class I or Class II device even if the original manufacturer never needed one.

Who Must Comply

The FDA's regulatory requirements apply to:

• Third-party reprocessors: Companies that collect used SUDs from healthcare facilities, reprocess them, and return them to the same or different facilities.
• Hospital reprocessors: Hospitals that reprocess SUDs in their own sterile processing departments for use within the same facility.

Both must register their establishments with the FDA, list the devices they reprocess, submit premarket applications, maintain quality systems, and comply with post-market reporting requirements.

FDA Premarket Requirements: 510(k) and PMA

Device Classification Determines Pathway

The premarket pathway for a reprocessed SUD depends on the device's classification, just as it does for new devices:

Classification	Premarket Pathway	Key Requirements
Class I	510(k) (even if OEM exempt)	Demonstrate substantial equivalence; cleaning/sterilization validation; functional testing
Class II	510(k)	Demonstrate substantial equivalence; cleaning/sterilization validation; functional testing; biocompatibility
Class III	PMA	Full premarket approval application; clinical data may be required; comprehensive risk analysis

The 510(k) Submission for Reprocessed SUDs

For the majority of reprocessed SUDs, the 510(k) pathway applies. The reprocessor must demonstrate that the reprocessed device is substantially equivalent to the OEM device (the predicate) in terms of intended use and technological characteristics.

Key elements of a 510(k) submission for a reprocessed SUD include:

1. Device description. Detailed description of the device, its intended use, and the reprocessing workflow.
2. Predicate device identification. Identification of the legally marketed OEM device to which substantial equivalence is being claimed.
3. Substantial equivalence discussion. Comparison of the reprocessed device to the predicate in terms of intended use, materials, design, and performance.
4. Cleaning and disinfection validation. Protocols and data demonstrating that the reprocessing cleaning procedure effectively removes all organic and inorganic contamination.
5. Sterilization validation. Protocols and data demonstrating that the reprocessed device can be sterilized to the appropriate sterility assurance level (SAL), typically 10^-6.
6. Functional performance testing. Data showing that the reprocessed device meets the same functional performance specifications as the new device.
7. Biocompatibility testing. Testing per ISO 10993 to confirm that the materials of the reprocessed device have not degraded or changed in ways that could affect biocompatibility.
8. Labeling. Proposed labeling that complies with FDA requirements for reprocessed devices.

Biocompatibility and Material Analysis

Biocompatibility is a critical component of the 510(k) submission for reprocessed SUDs. The reprocessor must demonstrate that the cleaning and sterilization processes do not degrade the device's materials or alter their biocompatibility profile. This requires:

• Material identification. Using analytical techniques such as Fourier Transform Infrared (FTIR) spectroscopy to identify the polymers and other materials used in the device. The reprocessor does not have access to the OEM's proprietary material specifications and must independently characterize the device.
• Material integrity testing. Verifying that repeated cleaning and sterilization cycles do not cause material degradation, embrittlement, cracking, or changes in mechanical properties.
• Biocompatibility evaluation per ISO 10993. The reprocessor must conduct or cite biocompatibility testing appropriate to the device's nature and body contact duration. This may include cytotoxicity, sensitization, irritation, and systemic toxicity testing.

FTIR spectroscopy is particularly important because it allows the reprocessor to identify unknown polymer materials by comparing the infrared absorption spectrum of the device material against reference spectra for known polymers. This information is essential for selecting appropriate cleaning agents and sterilization methods that will not damage the device.

The PMA Pathway for Class III Reprocessed SUDs

For Class III devices, the requirements are significantly more demanding. A Pre-market Approval (PMA) application is required, which may include:

• Clinical data to support the safety and effectiveness of the reprocessed device
• Comprehensive risk analysis
• Detailed manufacturing process description
• Non-clinical laboratory studies
• All of the elements required for a 510(k) submission, plus additional evidence

Class III SUDs that are commonly reprocessed include certain cardiovascular and electrophysiology devices. The PMA pathway means that reprocessors of Class III devices face a substantially higher regulatory burden.

FDA Post-Market Obligations for Reprocessors

Once a reprocessed SUD is on the market, the reprocessor must comply with the same post-market requirements as any other device manufacturer:

Quality Management System Regulation (QMSR)

As of February 2, 2026, the FDA's Quality Management System Regulation (QMSR) under 21 CFR Part 820 applies to all device manufacturers, including reprocessors. The QMSR incorporates ISO 13485:2016 by reference, meaning that reprocessors must maintain a quality management system that meets ISO 13485 requirements, with certain FDA-specific additions retained.

Key QMSR requirements for reprocessors include:

• Design controls (for any modifications to the reprocessing process)
• Production and process controls (for cleaning, testing, sterilization, and packaging)
• Corrective and preventive action (CAPA)
• Complaint handling and evaluation
• Device history record maintenance
• Traceability requirements

Medical Device Reporting (21 CFR Part 803)

Reprocessors must report adverse events and malfunctions to the FDA under the Medical Device Reporting (MDR) regulation:

• MDR reports (5-day and 30-day): Required when the reprocessed device may have caused or contributed to a death or serious injury, or when a malfunction that could cause or contribute to a death or serious injury recurs.
• Annual certification: Reprocessors must certify annually that they have submitted all required MDR reports or that no reportable events occurred.

Corrections and Removals (21 CFR Part 806)

If a reprocessor initiates a correction or removal of a reprocessed device to reduce a risk to health, they must report it to the FDA under 21 CFR Part 806.

Registration and Listing

All reprocessors must:

• Register their establishment with the FDA (annual registration)
• List each device they reprocess, including the device's classification, product code, and the OEM predicate device

Unique Device Identification (UDI)

UDI requirements apply to reprocessed devices. Reprocessors must assign UDI numbers and report device identifier information to the FDA's Global Unique Device Identification Database (GUDID). The UDI on a reprocessed device must allow traceability back to the reprocessor.

Labeling Requirements

FDA labeling requirements for reprocessed SUDs are specific and mandatory:

• Per Section 502(v) of the FD&C Act, the labeling must state: "Reprocessed device for single use. Reprocessed by [name of reprocessor]."
• The label must identify the reprocessor as the entity responsible for the device
• Any warnings, contraindications, or limitations on the number of reprocessing cycles must be included
• The labeling must not be misleading or conflict with the original device's intended use

Recommended Reading

MDSAP Audit Preparation: Complete Guide for Medical Device Manufacturers (2026)

MDSAP ISO 134852026-04-14 · 23 min read

EU MDR Article 17: The Current Framework

Article 17 Overview

Article 17 of the EU Medical Device Regulation (MDR 2017/745) governs the reprocessing of single-use devices within the European Union. It establishes the principle that SUD reprocessing is permitted only if the national law of the member state in question allows it.

This is a critical distinction from the FDA framework. While the FDA permits reprocessing nationwide (subject to regulatory compliance), the EU MDR leaves the decision to individual member states, creating a fragmented regulatory landscape.

Key Provisions of Article 17

1. Reprocessor treated as manufacturer. Any entity that reprocesses a single-use device to make it suitable for further use within the EU is considered the manufacturer of the reprocessed device. This means the reprocessor assumes all obligations of a manufacturer under the MDR, including conformity assessment, CE marking, post-market surveillance, and vigilance reporting.

2. National law determines permissibility. Article 17 does not itself permit or prohibit reprocessing -- it defers to national law. Member states may allow reprocessing, prohibit it, or allow it with specific conditions.

3. In-house reprocessing exception (Article 17(3)). Member states may decide not to apply all manufacturer obligations to healthcare institutions that reprocess SUDs for in-house use (within the same institution). This means that a hospital reprocessing devices for its own use may face a reduced regulatory burden compared to a third-party reprocessor, depending on the member state.

4. Common Specifications. Where reprocessing is permitted, it must comply with Common Specifications (CS) adopted by the European Commission. The CS provide detailed technical and quality requirements for reprocessing activities.

The Fragmented Landscape

The opt-in/opt-out structure of Article 17 has created an uneven landscape across the EU. Some member states have well-established reprocessing industries, while others prohibit the practice entirely. This fragmentation creates challenges for reprocessors seeking to operate across borders and for the EU's goal of a unified Single Market for medical devices.

Reprocessor Obligations Under Article 17

Where reprocessing is permitted, the reprocessor must:

• Assume full manufacturer responsibilities under the MDR
• Implement a quality management system compliant with the Common Specifications
• Conduct risk management activities specific to the reprocessing process
• Validate cleaning, sterilization, and functional testing processes
• Maintain comprehensive technical documentation
• Establish post-market surveillance and vigilance systems
• Apply CE marking to reprocessed devices (for third-party reprocessors)
• Maintain traceability records, including the number of reprocessing cycles performed on each device

Common Specifications Under EU MDR: Regulation 2020/1207

Overview

Commission Implementing Regulation (EU) 2020/1207 establishes the Common Specifications (CS) for the reprocessing of single-use devices under Article 17 of the MDR. These specifications provide the detailed technical requirements that reprocessors must meet and serve as a harmonized technical standard for reprocessing activities across the EU.

Key Areas Covered by the Common Specifications

The CS address the following areas:

Quality Management System

Reprocessors must implement and maintain a quality management system that covers all aspects of the reprocessing workflow. This includes documented procedures for:

• Receiving and inspecting incoming used devices
• Cleaning, disinfection, and sterilization
• Functional testing and inspection
• Packaging and labeling
• Release and distribution
• Complaint handling and corrective action

Risk Management

A formal risk management process aligned with ISO 14971 must be applied to the reprocessing of each device type. This includes:

• Identification of hazards associated with reprocessing (material degradation, residual contamination, functional failure)
• Risk estimation and evaluation
• Implementation of risk control measures
• Evaluation of residual risk
• Monitoring of risk control effectiveness through post-market surveillance

Validation

All reprocessing processes must be validated before the reprocessed device is placed on the market. Validation must cover:

• Cleaning validation: Demonstrating that the cleaning process removes organic and inorganic contamination to defined acceptance criteria
• Sterilization validation: Demonstrating that the sterilization process achieves the required sterility assurance level
• Functional testing validation: Demonstrating that the reprocessed device meets defined performance specifications

Documentation Requirements

The CS require comprehensive documentation, including:

• Reprocessing cycles: Documentation of the number of times a device has been reprocessed, with a defined maximum number of cycles
• Device history: Records tracing each device from receipt through reprocessing, testing, and distribution
• Technical documentation equivalent to that required for new devices under MDR Annexes II and III
• Contracts between healthcare facilities and external reprocessors specifying roles, responsibilities, and quality requirements

Labeling

Reprocessed devices must carry specific labeling, including:

• The word "reprocessed" prominently displayed
• The number of reprocessing cycles the device has undergone
• Identification of the reprocessor (name and address)
• Any limitations on further use
• Instructions for use that account for the reprocessed status of the device

Closed-Loop System

The CS establish a closed-loop system for reprocessed devices. Under this system:

• Reprocessed devices must be returned to the originating healthcare facility -- they cannot be freely distributed to any facility
• This traceability requirement ensures that devices are tracked throughout their lifecycle and that any facility receiving a reprocessed device knows its history
• The closed-loop system also supports recall capability and post-market surveillance

2026 EU Proposed Amendment: What Is Changing

Background

In December 2025, the European Commission released a proposed amendment to Article 17 of the MDR. The amendment addresses one of the most significant structural issues with the current framework: the fragmentation caused by allowing member states to individually decide whether to permit SUD reprocessing.

Key Changes Proposed

Removal of the Opt-In/Opt-Out Mechanism

The most consequential change in the proposed amendment is the removal of the paragraph that allows member states to decide individually whether to permit SUD reprocessing. Under the proposed amendment, reprocessing would be governed by centralized, harmonized rules applicable across all member states.

This change would:

• Eliminate the fragmented regulatory landscape that currently exists
• Create a uniform legal basis for reprocessing across the EU
• Support the integrity of the Single Market for medical devices
• Provide regulatory certainty for reprocessors seeking to operate in multiple member states

New Terminology: "Fully Refurbished Medical Devices"

The proposed amendment introduces the term "fully refurbished medical devices" to replace "reprocessed single-use devices." This terminological shift reflects an effort to:

• Distinguish reprocessed SUDs from routine reprocessing of reusable devices
• Align with concepts used in other regulated sectors (e.g., automotive and aerospace refurbishment)
• Potentially reduce stigma associated with the "reprocessed" label

Reprocessors Still Considered Manufacturers

The fundamental principle that reprocessors are manufacturers is retained in the proposed amendment. "Fully refurbishers" (the new term for reprocessors) must comply with all manufacturer obligations under the MDR, including:

• CE certification
• Conformity assessment
• Technical documentation
• Post-market surveillance
• Vigilance reporting

CE Certification Requirement

The amendment clarifies that reprocessors must obtain CE certification before marketing reprocessed (fully refurbished) devices. This requirement ensures that Notified Bodies assess the reprocessor's quality system, technical documentation, and risk management processes before devices enter the market.

Legislative Process and Timeline

The proposed amendment must go through the European Parliament and the European Council before it becomes law. This legislative process is expected to take at least six months, and potentially longer depending on the level of debate and any amendments proposed by Parliament or Council.

As of April 2026, the amendment is in the early stages of the legislative process. Companies should monitor developments closely and prepare for implementation.

Industry Reaction

The Association of Medical Device Reprocessors (AMDR) has expressed support for the proposed changes, describing them as restoring Single Market integrity. Third-party reprocessors operating in the EU have generally welcomed the harmonization effort, while some OEM industry groups have raised concerns about patient safety.

Recommended Reading

Best eQMS Software for Medical Devices 2026: Unbiased Comparison of Top Platforms

eQMS ISO 134852026-04-04 · 15 min read

TUV NORD Award: The First MDR Certificate for CE Reprocessing

A Landmark Achievement

In February 2026, TUV NORD awarded the first MDR certificate for CE reprocessing to Vanguard AG, a Germany-based reprocessor with over 25 years of experience in the field. This is a significant milestone for the reprocessing industry and for the EU regulatory framework.

Vanguard AG's CE Reprocessing Model

Vanguard AG has been operating Common Specifications (CS) and CE reprocessing since 2011. Under their CE reprocessing model:

• Vanguard assumes full manufacturer responsibility for the reprocessed devices
• This includes preparing and maintaining complete technical documentation for each device type
• Clinical evaluation is conducted and maintained as part of the technical documentation
• Post-market surveillance and vigilance systems are established and operated
• A Notified Body (TUV NORD) assesses and certifies the quality management system and technical documentation

The TUV NORD certification demonstrates that it is possible to meet the full manufacturer obligations under the MDR for reprocessed SUDs -- a significant proof point for the viability of the reprocessing industry under the current regulatory framework.

FDA vs. EU MDR: Comparison Table

The following table compares the key regulatory requirements for SUD reprocessing under the FDA and EU MDR frameworks:

Aspect	FDA (United States)	EU MDR Article 17
Legal basis	FD&C Act; 21 CFR Parts 803, 806, 820; MDUFMA	MDR (EU) 2017/745, Article 17; Implementing Regulation 2020/1207
Permissibility	Permitted nationwide, subject to regulatory compliance	Permitted only if national law allows; proposed amendment would harmonize across all member states
Reprocessor status	Considered a manufacturer	Considered a manufacturer
Premarket pathway	510(k) for Class I/II; PMA for Class III	CE certification via Notified Body conformity assessment
Quality system	QMSR (21 CFR 820, aligned with ISO 13485 as of Feb 2026)	QMS per Common Specifications; ISO 13485 typically required by Notified Bodies
Biocompatibility	Required per ISO 10993; FTIR for material identification	Required per ISO 10993; material analysis per CS
Cleaning validation	Required as part of 510(k)	Required per Common Specifications
Sterilization validation	Required as part of 510(k)	Required per Common Specifications
Functional testing	Required to demonstrate substantial equivalence	Required per Common Specifications
Labeling	Must state "Reprocessed device for single use. Reprocessed by [name]" per Section 502(v)	Must state "reprocessed" and include cycle count; specific CS requirements
UDI	Required; reported to GUDID	Required under MDR Article 27; reported to EUDAMED
Post-market surveillance	MDR reporting (21 CFR 803); corrections and removals (21 CFR 806)	PMS plan, PMCF, PSUR per MDR Article 84-86; vigilance per Article 87-90
Distribution	No closed-loop requirement (reprocessed devices can be distributed to any facility)	Closed-loop system: reprocessed devices must be returned to originating facility
Enforcement	FDA inspections; warning letters; injunctions; consent decrees	Notified Body surveillance audits; Competent Authority market surveillance
Hospital reprocessing	Subject to all OEM requirements	Member states may reduce obligations for in-house reprocessing (Article 17(3))
Exempt devices	Lose 510(k) exemption when reprocessed	N/A -- CE certification required regardless
Industry trade association	AMDR	AMDR (global representation)

Step-by-Step: Getting FDA 510(k) Clearance for Reprocessed SUDs

The following outlines the typical process for obtaining FDA 510(k) clearance for a reprocessed single-use device:

Step 1: Device Selection and Feasibility Assessment

• Identify the SUD to be reprocessed based on market demand, technical feasibility, and economic viability
• Assess the device's complexity, material composition, and number of components
• Evaluate whether the device can be adequately cleaned, sterilized, and functionally tested after use
• Review any known issues with the OEM device (complaints, recalls, adverse events)

Step 2: Material Characterization

• Use FTIR spectroscopy and other analytical methods to identify all materials used in the device
• Document material composition, including polymers, metals, adhesives, and coatings
• Assess material compatibility with planned cleaning agents and sterilization methods
• Identify any materials that may be susceptible to degradation during reprocessing

Step 3: Develop Reprocessing Protocol

• Design the reprocessing workflow: receiving, disassembly (if applicable), cleaning, inspection, functional testing, sterilization, packaging, labeling
• Develop cleaning validation protocols based on the device's design and clinical use
• Select and validate the sterilization method (EO, gamma, steam, or other appropriate method)
• Define acceptance criteria for each step of the process

Step 4: Conduct Validation Studies

• Cleaning validation: Demonstrate removal of organic soil (protein, hemoglobin, lipids) and inorganic contaminants to defined acceptance criteria. Use surrogate markers and worst-case testing.
• Sterilization validation: Validate the sterilization cycle per applicable standards (e.g., ISO 11135 for EO, ISO 17665 for steam). Demonstrate achievement of the required sterility assurance level.
• Functional performance testing: Test reprocessed devices against OEM performance specifications. Include testing after the maximum number of intended reprocessing cycles.
• Biocompatibility testing: Conduct ISO 10993 testing on reprocessed devices, including cytotoxicity, sensitization, and irritation at minimum.

Step 5: Prepare 510(k) Submission

• Compile the complete 510(k) application, including:
  • Cover letter and 510(k) summary or statement
  • Device description and intended use
  • Predicate device identification
  • Substantial equivalence comparison
  • Performance data (validation study results)
  • Biocompatibility data
  • Proposed labeling
• Use the FDA's eSTAR template for electronic submission
• Address specific eSTAR sections carefully, including biocompatibility, labeling, and performance testing

Step 6: FDA Review and Clearance

• FDA reviews the submission and may issue Additional Information (AI) requests
• Respond to AI requests within the specified timeframe
• Upon successful review, FDA issues a substantially equivalent (SE) letter
• The reprocessed device can then be legally marketed

Step 7: Post-Market Compliance

• Establish and maintain QMSR-compliant quality management system
• Implement MDR reporting procedures
• Establish complaint handling and CAPA processes
• Conduct ongoing post-market surveillance
• Maintain registration and listing

Recommended Reading

Medical Device Registration Cost by Country: 2026 Global Comparison

510(k) CE Marking2026-04-14 · 26 min read

Key Challenges for Reprocessors

Reprocessors face several unique challenges that distinguish them from traditional device manufacturers:

Lack of Access to OEM Design Information

Reprocessors do not have access to the OEM's proprietary design and manufacturing information, including:

• Detailed material specifications and supplier information
• Design history files and verification/validation data
• Process parameters and manufacturing tolerances
• Original sterilization validation data

This means reprocessors must independently reverse-engineer the device's material composition, develop their own cleaning and sterilization processes, and generate their own performance data -- all without the design intent knowledge that the OEM possesses.

Demonstrating Substantial Equivalence Without OEM Data

For 510(k) submissions, demonstrating substantial equivalence is more challenging when the reprocessor does not have access to the predicate device's design specifications. The reprocessor must:

• Independently characterize the device materials (using FTIR and other analytical techniques)
• Develop and validate cleaning processes without knowledge of the OEM's contamination profile expectations
• Establish performance criteria based on publicly available information and independent testing
• Address any FDA questions about equivalence without the ability to reference OEM test data

eSTAR Submission Challenges

The FDA's electronic Submission Template and Resource (eSTAR) system presents specific challenges for reprocessors:

• Biocompatibility section: The eSTAR template is structured for OEMs who select materials based on their design inputs. Reprocessors must adapt this section to describe materials identified through reverse-engineering and biocompatibility testing performed on reprocessed devices.
• Labeling section: The labeling requirements for reprocessed devices differ from those for new devices, and the eSTAR template may not perfectly accommodate these differences.
• Performance testing section: Reprocessors must present data that demonstrates the reprocessed device performs equivalently to the predicate, which requires a different evidentiary approach than a traditional 510(k).

Cycle Limit Determination

Reprocessors must determine the maximum number of times a device can be safely reprocessed. This requires:

• Accelerated aging studies on reprocessed devices
• Functional testing at increasing cycle counts
• Material integrity analysis at each cycle
• Biocompatibility testing at the maximum intended cycle count
• Statistical justification for the selected cycle limit

Supply Chain and Device Condition Variability

Unlike OEMs who manufacture devices from raw materials under controlled conditions, reprocessors receive devices that have been used in clinical settings. The condition of returned devices varies significantly:

• Different degrees of contamination
• Different levels of mechanical wear
• Potential damage from clinical use
• Variability in how the device was handled after use

Reprocessors must establish robust incoming inspection and sorting procedures to identify devices that are suitable for reprocessing and reject those that are not.

Country-by-Country: EU Member State Reprocessing Rules

The following table summarizes the reprocessing landscape in selected EU member states. Note that this landscape may change significantly if the proposed amendment to Article 17 is adopted.

Country	Reprocessing Permitted?	Key Conditions	Notes
Germany	Yes	Full regulatory framework; third-party and in-house reprocessing permitted	Largest reprocessing market in the EU; home to Vanguard AG and several other reprocessors
Netherlands	Yes	Regulatory framework established; oversight by Health and Youth Care Inspectorate	Active reprocessing market with established quality standards
Spain	Yes	Permitted with conditions; national regulatory framework in place	Growing reprocessing activity
Sweden	Yes	Permitted under certain conditions	Scandinavian healthcare systems have embraced reprocessing as part of sustainability efforts
France	Restricted	Historically restrictive approach; limited reprocessing permitted	Policy has evolved but remains more restrictive than Germany or Netherlands
United Kingdom	N/A (post-Brexit)	Governed by UK MHRA regulations, not EU MDR Article 17	UK regulatory framework for reprocessing differs from EU
Italy	Limited	Limited reprocessing permitted under specific national provisions	Regulatory framework less developed than Germany
Denmark	Varies	Scandinavian approach generally more permissive	Specific national rules apply

Note: The regulatory landscape in the EU is evolving. The proposed amendment to Article 17, if adopted, would establish uniform rules across all member states, eliminating the current variation. Companies should consult with regulatory counsel for the most current information on specific countries.

FAQ: Single-Use Device Reprocessing

What is a single-use device?

A single-use device (SUD) is a medical device that the original manufacturer has labeled as intended for one episode of use on a single patient. The labeling determination is made by the OEM based on their risk analysis and design validation. SUDs are not intended to be reused, but reprocessing allows them to be cleaned, sterilized, and returned to clinical use under regulated conditions.

Is reprocessing of single-use devices legal?

Yes, in the United States, reprocessing is legal nationwide provided the reprocessor complies with all FDA regulatory requirements applicable to device manufacturers, including premarket submission (510(k) or PMA), quality system requirements, and post-market reporting. In the European Union, reprocessing is permitted only in member states whose national law allows it, subject to the requirements of MDR Article 17 and the Common Specifications.

Does the FDA consider reprocessed devices safe?

The FDA has stated that "reprocessed SUDs that meet FDA's regulatory requirements are as safe and effective as a new device." The GAO has also determined that available data do not indicate an elevated health risk to patients from properly reprocessed devices. FDA requires reprocessors to demonstrate substantial equivalence or safety and effectiveness before marketing reprocessed devices.

Why do OEMs label devices as single-use?

OEMs label devices as single-use based on their design validation, risk analysis, and intended use. Reasons include: the device materials may not withstand repeated sterilization; the device design may not allow adequate cleaning of all surfaces; the manufacturer has not validated the device for multiple uses; or the manufacturer's business model is based on single-use sales. The single-use designation is the OEM's determination, not a regulatory requirement in most cases.

How much can hospitals save by using reprocessed devices?

Hospitals typically save 30-50% on device acquisition costs by using reprocessed SUDs compared to purchasing new OEM devices. For a mid-sized hospital performing thousands of procedures annually, this can translate to hundreds of thousands of dollars in annual savings. The exact savings depend on the device types and volumes reprocessed.

What is FTIR spectroscopy and why is it used in reprocessing?

Fourier Transform Infrared (FTIR) spectroscopy is an analytical technique used to identify the chemical composition of materials by measuring their absorption of infrared light at different wavelengths. In SUD reprocessing, FTIR is used to identify the polymers and other materials in the device, since reprocessors do not have access to the OEM's proprietary material specifications. This information is essential for selecting compatible cleaning agents and sterilization methods and for conducting biocompatibility assessments.

What is the difference between third-party reprocessing and hospital in-house reprocessing?

Third-party reprocessing is performed by specialized companies (such as Innovative Health, Cardinal Health Sustainable Technologies, or Vanguard AG) that collect used SUDs from healthcare facilities, reprocess them in controlled environments, and return them. Hospital in-house reprocessing is performed by the healthcare facility's own sterile processing department. Under FDA regulations, both are subject to the same regulatory requirements as OEMs. Under the EU MDR, member states may reduce certain obligations for in-house reprocessing under Article 17(3).

What are the Common Specifications under the EU MDR?

The Common Specifications (CS) are established by Commission Implementing Regulation (EU) 2020/1207 and provide detailed technical and quality requirements for SUD reprocessing in the EU. They cover quality management systems, risk management, validation of cleaning and sterilization processes, documentation requirements (including reprocessing cycle counts and device history), labeling (including the word "reprocessed" and cycle counts), and contracts between healthcare facilities and external reprocessors.

What is the closed-loop system in EU reprocessing?

The closed-loop system required by the EU Common Specifications mandates that reprocessed devices must be returned to the originating healthcare facility. This means a reprocessed device cannot be freely distributed to any hospital -- it must go back to the same institution that originally sent it for reprocessing. This supports traceability, recall capability, and post-market surveillance.

What changes are proposed for EU SUD reprocessing in 2026?

The European Commission's proposed amendment to MDR Article 17, released in December 2025, would remove the member state opt-in/opt-out mechanism and establish centralized, harmonized rules for reprocessing across all EU member states. It introduces the term "fully refurbished medical devices" and retains the principle that reprocessors are manufacturers who must obtain CE certification. The amendment is currently progressing through the European Parliament and Council, with the legislative process expected to take at least six months.

Conclusion

Single-use device reprocessing occupies a unique position in the medical device regulatory landscape. It is simultaneously an economic strategy for healthcare cost containment, an environmental initiative aligned with circular economy principles, and a heavily regulated manufacturing activity that requires the same level of rigor as original device manufacturing.

In the United States, the regulatory framework is well-established: reprocessors are manufacturers, subject to the full range of FDA requirements from premarket review through post-market surveillance. The EU framework is evolving, with the current fragmented approach under MDR Article 17 potentially giving way to harmonized rules across all member states through the proposed 2026 amendment.

For companies considering entry into the reprocessing space, the regulatory requirements are demanding but navigable. Success depends on rigorous process validation, thorough material characterization, robust quality management systems, and a clear understanding of both the FDA and EU MDR requirements. The TUV NORD certification of Vanguard AG in February 2026 demonstrates that achieving full MDR compliance for reprocessed devices is achievable, and the industry is likely to continue growing as healthcare systems worldwide seek cost-effective and sustainable solutions.